EMP16 (Empros Pharma)

**EMP16** is an oral, modified-release fixed-dose combination of **orlistat** and **acarbose** being developed by Empros Pharma for chronic weight management and obesity. The formulation is designed to release the locally acting agents in targeted regions of the gastrointestinal tract to improve the efficacy-tolerability balance of conventional formulations. Orlistat inhibits gastrointestinal lipases and reduces dietary triglyceride hydrolysis and fat absorption, while acarbose inhibits intestinal carbohydrate-digesting enzymes, delaying carbohydrate digestion and glucose absorption. Phase 2 studies have reported placebo-adjusted weight loss and no unexpected safety findings, while an additional Phase 2 pilot study evaluated gastrointestinal tolerability during dose escalation with dietary fiber support.

Other names

controlled-release orlistat-acarbosemodified-release orlistat + acarbose